Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031

Abstract

Our group previously demonstrated a strong association between elevated plasma soluble CD13 enzyme activity and newly diagnosed extensive chronic GVHD (cGVHD) in children. As cytotoxic anti-CD13 Abs have been documented after blood and marrow transplant (BMT) in association with CMV infection and cGVHD, we hypothesized that soluble CD13 contributes to cGVHD pathogenesis by induction of CD13 reactive Abs and that anti-CD13 Abs could be additional biomarkers for newly diagnosed pediatric extensive cGVHD. Using prospectively collected plasma samples from pediatric allogeneic BMT (allo-BMT) subjects with cGVHD and controls without cGVHD enrolled in a large multi-institution Children's Oncology Group cGVHD therapeutic trial, we evaluated whether soluble CD13 correlates with induction of anti-CD13 Abs. We found that CD13 reactive Abs are present in a proportion of patients after allo-BMT, but did not seem to correlate with the presence of soluble CD13. Anti-CD13 Abs also did not meet our criteria as a diagnostic biomarker for cGVHD. These data do not confirm that induction of CD13 reactive Abs is a mechanism for cGVHD in children nor are part of the pathogenesis of cGVHD associated with elevated soluble CD13. The exact role of CD13 in cGVHD remains to be determined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O . Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548–551.

    Article  CAS  Google Scholar 

  2. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043–2051.

    Article  CAS  Google Scholar 

  3. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versushost disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.

    CAS  PubMed  Google Scholar 

  4. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  5. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108: 2867–2873.

    Article  CAS  Google Scholar 

  6. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    Article  CAS  Google Scholar 

  7. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: A report from the Children's Oncology Group. Blood 2008; 111: 3276–3285.

    Article  CAS  Google Scholar 

  8. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z et al. Altered toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 386–397.

    Article  CAS  Google Scholar 

  9. Luan Y, Xu W . The structure and main functions of aminopeptidase N. Curr Med Chem 2007; 14: 639–647.

    Article  CAS  Google Scholar 

  10. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL et al. Expression of aminopeptidase-n (CD13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 1994; 47: 43–47.

    Article  CAS  Google Scholar 

  11. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E . CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation 1996; 61: 594–600.

    Article  CAS  Google Scholar 

  12. Soderberg C, Larsson S, Rozell B, Sumitran-Karuppan S, Ljungman P, Moller E . Cytomegalovirus-induced CD13 specific autoimmunity—a possible cause of chronic graft-versus-host disease. Transplantation 1996; 61: 600–609.

    Article  CAS  Google Scholar 

  13. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973–2978.

    Article  CAS  Google Scholar 

  14. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237–241.

    Article  CAS  Google Scholar 

  15. Soderberg C, Giugni TD, Zaia JA, Larsson S, Wahlberg JM, Moller E . CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol 1993; 67: 6576–6585.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Giugni TD, Soderberg C, Ham DJ, Bautista RM, Hedlund KO, Moller E et al. Neutralization of human cytomegalovirus by human CD13-specific antibodies. J Infect Dis 1996; 173: 1062–1071.

    Article  CAS  Google Scholar 

  17. Hansen AS, Noren O, Sjostrom H, Werdelin O . A mouse aminopeptidase N is a marker for antigen presenting cells and appears to be co-expressed with major histocompatibility complex class II molecules. Eur J Immunol 1993; 23: 2358–2364.

    Article  CAS  Google Scholar 

  18. Falk K, Rotzschke O, Stavanovic S, Jung G, Rammensee HG . Pool sequencing of natural HLA-DR, DQ and DP ligands reveal detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994; 39: 230–242.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Ruth Milner for her expert statistical help and Dr Kaiji Hu for assistance with Cellomics. This work was supported by Grant RO1-CA84137 from the National Cancer Institute of the National Institutes of Health and by the Canadian Institutes of Health Research/Wyeth Clinical Research Chair in Transplantation. Chair's U10 CA98543.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K R Schultz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cuvelier, G., Kariminia, A., Fujii, H. et al. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031. Bone Marrow Transplant 45, 1653–1657 (2010). https://doi.org/10.1038/bmt.2010.15

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.15

Keywords

This article is cited by

Search

Quick links